Recombinant adeno-associated virus (AAV) vectors are predominantly nonintegrating, but rare genomic integration events have been associated with oncogenesis in neonatal murine models. Here we ...
In a recent review published in Signal Transduction and Targeted Therapy, researchers presented recombinant adeno-associated virus (rAAV)-based genetic applications to treat human diseases. Study: ...
The CHOP's research team findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which ...
Four patients with infantile-onset Pompe’s disease received a single intravenous injection of an adeno-associated virus serotype 9 vector carrying codon-optimized complementary DNA encoding human acid ...
Safety issues linked to adeno-associated virus (AAV) gene therapies, including patient deaths tied to liver toxicity, are prompting developers to explore non-viral delivery methods. Alternatives such ...
Oral presentation at ASGCT showcases breakthrough technology enabling precise in vivo genome editing in the CNS using a ...
Adeno-associated viruses (AAVs) are as small, replication-defective, non-enveloped viruses, serving as vectors for gene therapy. AAV vectors play a transformative role in delivering therapeutic genes ...
Osaka, Japan - A research team at The University of Osaka has unveiled the molecular mechanism behind genome ejection from adeno-associated virus (AAV) vectors, a crucial delivery vehicle in gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results